Prurigo nodularis (PN) is a chronic inflammatory skin condition characterized by severely pruritic skin nodules.
Monoclonal antibody inhibiting signaling through oncostatin M receptor beta (OSMRβ).
KPL-716 inhibits signaling of interleukin-31 (IL-31) and oncostatin M (OSM), 2 key cytokines implicated in inflammation, pruritus, and fibrosis.
We estimate that there are approximately 300,000 patients with PN in the United States.
Studies link many pruritic and inflammatory diseases to both IL-31 and OSM via signaling through OSMRβ. By targeting both pathways simultaneously, KPL-716 may disrupt the pathologic cycle in patients afflicted by a variety of pruritic diseases.
We are currently enrolling a randomized, double-blind, placebo-controlled, adaptive design Phase 2a clinical trial of KPL-716 in subjects with PN.
We are currently enrolling an exploratory Phase 2 clinical trial of KPL-716 in diseases characterized by chronic pruritus.
We are not aware of any current therapies approved by the FDA for the treatment of PN.